Bioelectronics player Rio Grande quits $21.5M Endonovo deal

Rio Grande Therapeutics, the electroceuticals maker that inked a $21.5 million agreement to be acquired by fellow bioelectronics player Endonovo last month, has pulled out of the deal.

Rio Grande CEO Steven Gluckstern terminated the binding letter of intent Friday, following a request to renegotiate the terms of the agreement, according to an Endonovo statement. “Our board of directors has determined we are better served by this decision,” Endonovo said.

Endonovo has canceled the $500,000 note it issued toward the $21.5 million buyout. The California-based company had planned to hand over $15 million in Endonovo common stock, $5 million in Endonovo warrants and $1.5 million in cash as part of the transaction.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The duo announced in early July that they planned to sign an agreement in the quarter ending Sept. 30. Endonovo--which markets a noninvasive bioelectronic device to treat or ward off organ failure brought on by inflammation and necrosis--stood to gain all of Rio Grande’s products, including its FDA-cleared tPEMF tech for the treatment of postsurgical neuroinflammation.

"We believe this acquisition will significantly increase Endonovo's trajectory as we continue developing our non-invasive treatments for acute inflammatory conditions in vital organs," said Endonovo CEO Alan Collier at the announcement of the deal. "The combined company creates greater shareholder value for both RGN and Endonovo and will further establish Endonovo at the forefront of bioelectronic medicine."

The deal would have boosted Endonovo’s reach in the rising bioelectronics/electroceuticals field, which players like pharma giant GlaxoSmithKline ($GSK) are trying to get in on. It rests on the premise that the body’s electrical impulses can be manipulated to heal itself from illness. The goal is to create implantable bioelectronic devices that could potentially cause biochemical changes in the body that are traditionally brought on by drugs.

- here's the statement

Related Articles:
Endonovo inks $21.5M deal to pick up electroceuticals maker Rio Grande
GSK dives deeper into electroceuticals with clinical trials on the horizon
Electroceuticals startup NeuSpera raises $8M to back tiny, injectable neuromodulation tech


Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.